Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

医学 中止 内科学 临床终点 耐火材料(行星科学) 临床研究阶段 淋巴瘤 胃肠病学 肿瘤科 临床试验 天体生物学 物理
作者
Yuqin Song,Luis Malpica,Qingqing Cai,Weili Zhao,Keshu Zhou,Jianqiu Wu,Huilai Zhang,Neha Mehta‐Shah,Kaiyang Ding,Yao Liu,Zengjun Li,Liling Zhang,Meifang Zheng,Jie Jin,Haiyan Yang,Yue-Rong Shuang,Dok Hyun Yoon,Sujun Gao,Wenyu Li,Zhimin Zhai
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (1): 117-125 被引量:19
标识
DOI:10.1016/s1470-2045(23)00589-2
摘要

Background Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, has shown encouraging anti-tumour activity in heavily pre-treated patients with relapsed or refractory peripheral T-cell lymphoma in a phase 1 study (JACKPOT8 Part A). Here, we report the full analysis of a phase 2 study, in which we assessed the anti-tumour activity of golidocitinib in a large multinational cohort of patients. Methods We did a single-arm, multinational, phase 2 trial (JACKPOT8 Part B) in 49 centres in Australia, China, South Korea, and the USA. Eligible patients were adults (aged ≥18 years) with relapsed or refractory peripheral T-cell lymphoma who had received at least one previous line of systemic therapy and an Eastern Cooperative Oncology Group performance status of 0–2. Patients were given oral golidocitinib 150 mg once daily until disease progression or other discontinuation criteria were met. The primary endpoint was the CT-based objective response rate, assessed by an independent review committee (IRC) per Lugano 2014 classification. The activity analysis set included all patients who received at least one dose and whose pathological diagnosis of peripheral T-cell lymphoma had been retrospectively confirmed by a central laboratory and who had at least one measurable lesion at baseline assessed by IRC. The safety analysis set included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT04105010, and is closed to accrual and follow-up is ongoing. Findings Between Feb 26, 2021, and Oct 12, 2022, we assessed 161 patients for eligibility, of whom 104 (65%) were enrolled and received at least one dose of study drug; the activity analysis set included 88 (85%) patients (median age 58 years [IQR 51–67], 57 [65%] of 88 were male, 31 [35%] were female, and 83 [94%] were Asian). As of data cutoff (Aug 31, 2023; median follow-up was 13·3 months [IQR 4·9–18·4]), per IRC assessment, the objective response rate was 44·3% (95% CI 33·7–55·3; 39 of 88 patients, p<0·0001), with 21 (24%) patients having a complete response and 18 (20%) having a partial response. In the safety analysis set, 61 (59%) of 104 patients had grade 3–4 drug-related treatment-emergent adverse events. The most common grade 3–4 drug-related treatment-emergent adverse events were neutrophil count decreased (30 [29%]), white blood cell count decreased (27 [26%]), lymphocyte count decreased (22 [21%]), and platelet count decreased (21 [20%]), which were clinically manageable and reversible. 25 (24%) patients had treatment-related serious adverse events. Deaths due to treatment-emergent adverse events occurred in three (3%) patients: two (2%) due to pneumonia (one case with fungal infection [related to golidocitinib] and another one with COVID-19 infection) and one (1%) due to confusional state. Interpretation In this phase 2 study, golidocitinib showed a favourable benefit–risk profile in treating relapsed or refractory peripheral T-cell lymphoma. The results of this study warrant further randomised clinical studies to confirm activity and assess efficacy in this population. Funding Dizal Pharmaceutical.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
梦想在飞发布了新的文献求助10
刚刚
量子星尘发布了新的文献求助30
1秒前
大胆嘞完成签到 ,获得积分10
1秒前
1秒前
科目三应助高lucky采纳,获得10
1秒前
啦啦啦完成签到,获得积分10
2秒前
2秒前
xnzll完成签到,获得积分10
3秒前
奥利奥爱好者完成签到,获得积分10
3秒前
hdy关注了科研通微信公众号
4秒前
寒冷的咖啡应助可爱板栗采纳,获得20
4秒前
5秒前
光亮笑柳发布了新的文献求助10
5秒前
黑黑黑发布了新的文献求助10
5秒前
han完成签到,获得积分20
5秒前
CodeCraft应助LL采纳,获得10
6秒前
6秒前
照照完成签到,获得积分20
7秒前
歪歪完成签到,获得积分10
8秒前
9秒前
10秒前
想发SCI发布了新的文献求助10
10秒前
10秒前
FashionBoy应助梦想在飞采纳,获得20
10秒前
11秒前
张业轩完成签到,获得积分10
11秒前
梨江鱼完成签到,获得积分10
12秒前
梦XING发布了新的文献求助10
13秒前
Vincenzo发布了新的文献求助10
13秒前
AAA卡车司机完成签到,获得积分10
13秒前
臭学医的完成签到,获得积分20
13秒前
慢慢不吃梨子完成签到,获得积分10
14秒前
14秒前
14秒前
搞怪白秋完成签到 ,获得积分10
14秒前
爬得飞快的仲文博完成签到,获得积分10
14秒前
14秒前
水果发布了新的文献求助10
14秒前
冬去春来发布了新的文献求助10
15秒前
hdy发布了新的文献求助10
16秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974797
求助须知:如何正确求助?哪些是违规求助? 3519250
关于积分的说明 11197623
捐赠科研通 3255405
什么是DOI,文献DOI怎么找? 1797769
邀请新用户注册赠送积分活动 877156
科研通“疑难数据库(出版商)”最低求助积分说明 806202